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The Sandwich Technique for Hypogastric Endorevas-
cularization Using Off The Shelf Devices: Three-Year
Results
Armando Lobato, Luciana Camacho-Lobato. ICVE, Sao
Paulo, Brazil
Objectives: To analyze early and mid-term outcomes
in patients undergoing the Sandwich Technique, hypogas-
tric artery (HA) endorevascularization (ER), to treat com-
plex aortoiliac aneurysms (AIA), isolated common iliac
artery aneurysm (ICIAA) and abdominal aortic aneurysms
(AAA) associated with bilateral short, non-diseased com-
mon iliac artery (CIA).
Methods: Between October 2008 and November
2011 52 patients undergoing elective endovascular aneu-
rysm repair (EVAR) for AIA, ICIAA, or AAA with short,
non-diseased CIA were treated using the Sandwich Tech-
nique. Patients were followed through office visits and
CTA Demographic, clinical, and anatomical parameters
and outcomes were recorded. Statistical analysis included
descriptive and non parametric statistical tests (Kruskal-
Wallis and Dunns post Test) for aneurysm sac diameter
assessment (Prism 5, Graphpad Software).
Results: The mean age of the cohort was 73.8 years
and 92.3% of patients were male. The mean follow-up was
15  7.4 months . There was no peri-operative mortality.
60 HA ER (eight patients submitted a bilateral HA ER)
were performed during this prospective study. HA ER
technical success was 100%. Two-year primary HA ER
patency was 93.3%. One late type III endoleak have ap-
peared at 6 months and was not associated with aneurysm
sac enlargement. At three-year, the overall mortality rate
was 3.8%, all unrelated with aneurysm sac rupture. The
assessment of the CIA aneurysm sac diameter by CTA
revealed that 38.3% CIAA had a significant decrease (
least 5 mm), 60% remained stable and 1.7% had an increase
of 6mm. Statistical significance (P.05) was reached only
for comparisons between baseline (0 months) and 30
month measurements (P.027).
Conclusions: The Sandwich Technique, developed to
overcome current anatomical and device constraints, has
the promise of expanding the limits of endovascular aneu-
rysm repair (EVAR) in a safe, easy to perform, and cost-
effectivemanner. It is a useful tool in the armamentarium of
the endovascular surgeon.
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Management of the Left Subclavian Artery and Stroke
after TEVR: Lessons from 1000 Cases in the
MOTHER Registry
Benjamin O. Patterson1, Peter J. Holt1, Alan Karthikesal-
ingam1, Ian M. Loftus1, Ron M. Fairman2, Matt M.
Thompson1. 1St Georges’ Vascular Institute, London,
United Kingdom; 2Hospital of the University of Pennsyl-
vania, Philadelphia, PA
Objectives: Endovascular repair of thoracic aortic an-
eurysms and dissections (TEVR) has been associated with
peri-operative stroke rates as high as 15% in some series.
The objective of this study was to determine the incidence
of peri-operative stroke following TEVR and to define
subsets of patients at increased risk.
Methods: The MOTHER registry is an amalgamation
of five sponsored trials and a single institutional case series
with detailed data on 1010 TEVR. In this study, the
peri-operative stroke rate was investigated. Differences be-
tween groups were quantified through logistic regression
and by comparison of proportions.
Results: Of the 1010 cases, 48 (4.8%) of patients had a
stroke within 30 days. Of these 4 (8.3%) were fatal, but 14
(30%) made a recovery without deficit. Multiple regression
analysis demonstrated that female gender (OR1.9; 95%
CI 1.1-3.4; P.042), renal insufficiency (OR2.1; 95% CI
1.1-4; P.036), history of CVA (OR2.4; 95% CI 1.2-
4.8; P.000) and covering the left subclavian artery with-
out revascularisation (OR 3.6; 95% CI 1.9-6.5; P.000)
were independently predictive of peri-operative stroke.
Mode of admission and type of pathology were not of
significant influence.
Conclusions: Coverage of the left subclavian artery
without re-vascularisation would appear to be the single
most important predictior of post-TEVAR stroke. Not only
is this a strong association, but is potentially modifiable by
appropriate re-vascularisation procedures.
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Aortic Aneurysms Following EVAR
Benjamin J. Herdrich, Erin M. Murphy, Grace J. Wang,
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Objectives: There are many patients treated with
EVAR who have a concomitant aneurysm of the suprarenal
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aorta (sAAA). The natural history of these sAAAs and
whether they affect the results of EVAR are unknown.
Methods: 470 patients in theM2S database were iden-
tified as having an infrarenal abdominal aortic aneurysm
(iAAA) with a concomitant sAAA (diameter 2.9-4.7cm).
Patients with a preoperative CTA and follow-up imaging
12 months (n239) were included in the analysis. Pa-
tients who did not undergo EVAR served as a control (C)
(n81). Patients with EVARwere subdivided into suprare-
nal fixation (SR) (n94) and infrarenal fixation(IR)
(n64). Standard measurements from the M2S images
were extracted, and growth rates were calculated for differ-
ent abdominal aortic segments.
Results: The average follow-up was 32.1  19.8
months. The average initial size and growth rate of the sAAA
was 34.503.31mm and 0.561.35mm/yr for patients un-
dergoing EVAR (SRIR) compared with 36.683.67mm
(P.05) and 0.602.87mm/yr (P.17) for controls. Fol-
lowing EVAR, 1.3% of patients (SR-1/941.1%; IR
1/641.6%) experienced sAAA growth to a diameter
50mmwhichwas not significantly different from the control
group (4/814.9%, P.09) and occurred at a mean of 43.5
months (range 9.8-59.4). Comparing the SR and IR
groups, there was no difference in the preoperative sAAA
diameter (SR 34.663.09mm, IR 34.263.61, P.75).
Postoperative sAAA growth rate (SR 0.561.20mm/yr, IR
0.551.55, P.98), aortic growth rate at the renals (SR
1.001.81mm/yr, IR 0.901.50, P.69), iAAA growth
rate (SR -1.685.79mm/yr, IR -1.385.09, P.73), and
iAAA change in volume (SR -10.5834.65mL/yr, IR
-6.1129.14, P.40) were also not significantly different.
Conclusions: Isolated treatment of iAAA via EVAR
with a concomitant sAAA is acceptable as the endograft
(suprarenal or infrarenal) does not affect growth rates of the
sAAA. Standard EVAR follow-up is all that is required as
only a small minority demonstrate growth.
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Obstruction of the Endurant Endograft Post-EVAR:
Incidence and Treatment Results
Laura van Zeggeren1, Joost A. van Herwaarden2, Hence J.
Verhagen3, Debbie A. Werson1, Herman J. Zandvoort2,
Frederico B. Goncalves3, Frans L. Moll2, Jean-Paul P. de
Vries1. 1Vascular Surgery, St. Antonius Hospital, Nieu-
wegein, Netherlands; 2UniversityMedical Center, Utrecht,
Netherlands; 3Erasmus Medical Center, Rotterdam,
Netherlands
Objectives: The Endurant endograft was specially de-
veloped to broaden the treatment range for EVAR in
patients with complex aortoiliac anatomy. Preliminary re-
ports showed excellent outcome concerning migration and
type IA endoleaks, but occurrence of post-EVAR obstruc-
tion has not been determined in a large patient cohort with
mid-term follow-up (FU).
Methods: Data of all consecutive patients treated with
the Endurant from December 2007 to April 2011 in 3
Dutch tertiary referral hospitals were prospectively gath-
ered. FU consisted of regular office visits, 1 and 12 months
CT-scans, and annual duplex scanning thereafter. Patients
with either a symptomatic stenosis or complete occlusion of
the Endurant endograft were identified.
Results: 428 patients (88.3% male, mean age 73 years
(range 47-89)) were treated. Median FU was 12 months
(range 0-43). 22 obstructions occurred in 21 patients
(4.9%), either of the main body of the graft (n3), a limb
(n18) or unknown (n1). Median time to obstruction
was 6 months (range 0-22), with 27.3% occurring 12
months post-EVAR. Presenting symptoms were acute isch-
emia (40.9%, Rutherford 2A-B) or non acute (59.1%). The
latter were mainly claudicants without rest pain, and diag-
nosed at regular FU. Treatment was surgical (63.6%) or
percutaneous (18.2%), the remainder was left untreated
due to mild clinical complaints. Initial treatment was suc-
cessful in 19 of 22 obstructions (86.4%), but re-obstruction
occurred in 6 (31.6%). In 40.9%of obstructions a graft related
complication (kinking, stenosis or collapse) was found. Mor-
tality due to obstruction of the endograft was 0.7% (3/428) in
all patients, and 14.3% (3/21) in the obstruction group; 2
patients died because of ongoing ischemia, and 1 patient died
intra-operatively due to bleeding.
Conclusions: Endurant endograft obstruction oc-
curred in 4.9% of 428 patients, and continued during FU.
It is an important complication that must be considered in
expanding the indications for EVAR.
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